Mektovi (binimetinib) — United Healthcare

Initial criteria

• Diagnosis of melanoma
• Disease is unresectable OR metastatic
• EITHER (patient positive for BRAFV600 mutation AND used in combination with Braftovi (encorafenib)) OR (patient positive for NRAS mutation AND progression after prior immune checkpoint inhibitor therapy)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Mektovi therapy
• EITHER (BRAFV600 mutation positive AND used in combination with Braftovi (encorafenib)) OR (NRAS-mutated tumor)

Approval duration

12 months